Sudeep Pharma Limited announced the outcome of its Board Meeting held on December 19, 2025. The Board considered and approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. The meeting commenced at 02:00 p.m. and concluded at 03:20 p.m. The company also provided detailed financial statements for the standalone and consolidated entities for the quarter and year-to-date period ended September 30, 2025. For the standalone results, total income for the quarter was ₹10,070.90 lakhs, with a profit before tax of ₹3,990.32 lakhs and profit for the period of ₹2,974.14 lakhs. For the consolidated results, total income for the quarter was ₹17,283.17 lakhs, with a profit before tax of ₹5,953.37 lakhs and profit for the period of ₹4,677.82 lakhs. Subsequent to the quarter, Sudeep Pharma completed an Initial Public Offering (IPO) and its shares were listed on the NSE and BSE on November 28, 2025. The company also noted that the financial results for the previous quarters were not subjected to limited review as the requirement of submission of quarterly standalone financial results is applicable only after the listing of equity shares.